1-Cyclopropyl-6,8-difluoro-7-((4aS,7aS)-hexahydro-1H-pyrrolo[3,4-b]pyridin-6(2H)-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, with CAS number 151213-15-9, is a chemical compound known as Moxifloxacin EP Impurity A. It is structurally related to the broad-spectrum fluoroquinolone antibiotic moxifloxacin, differing by the presence of a hexahydro-1H-pyrrolo[3,4-b]pyridin-6(2H)-yl group at the 7-position instead of the octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group found in the active pharmaceutical ingredient (API). This compound is primarily used as a reference standard or impurity standard in the pharmaceutical industry. It is critical for the quality control and analytical testing of moxifloxacin drug substances and finished products. Regulatory bodies, such as the European Pharmacopoeia (EP), require the identification, quantification, and control of such process-related impurities to ensure drug safety, efficacy, and compliance with stringent specifications. As a designated pharmacopoeial impurity, it is essential for method validation, stability studies, and batch release testing. Handling requires standard laboratory safety precautions for fine chemicals. Its primary commercial value lies in its role as a high-purity certified reference material for analytical purposes, rather than as a therapeutic agent itself.